Stocktoria
Forte Biosciences, Inc. FBRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-04-13
Forte Biosciences, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating income | -$70.7M | -$36.6M | -$32.5M | -$13.9M | -$21.5M |
| Income tax | $1.0M | $0 | — | — | — |
| Net income | -$69.4M | -$35.5M | -$31.5M | -$13.9M | -$21.7M |
| EPS (diluted) | $-4.71 | $-12.17 | $-24.92 | $-0.80 | $-1.55 |
| Operating cash flow | -$50.9M | -$30.7M | -$28.7M | -$8.2M | -$16.7M |
| Free cash flow | -$51.0M | -$30.8M | -$28.8M | — | — |
| Cash & equivalents | $77.0M | $22.2M | $37.1M | $41.1M | $42.0M |
| Total assets | $82.8M | $61.6M | $39.0M | $42.0M | $43.3M |
| Total liabilities | $21.8M | $9.1M | — | — | — |
| Shareholders' equity | $61.0M | $52.5M | $35.3M | $38.8M | $41.5M |
Source: SEC EDGAR filings · CIK 0001419041 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.